Jan. 5 at 2:17 PM
$XXII's cap table is a disaster. Warrant holders and preferred shareholders control the company. Even if a miracle happened and the FDA issued a VLN mandate for all cigarettes in the US (which is incredibly unlikely IMHO), common shareholders would see ZERO upside. The company's (i) planned equity raise(s), (ii) new reverse split, (iii) constraints posed by its Nasdaq listing, (iv) incompetence of management (all of whom have ZERO cpg experience), and (v) anti-dilution protections for preferred shareholders give XXII common stock investors literally ZERO upside from here.
In the meantime,
$CHUC has become the best tobacco harm reduction stock on the market.
$CHUC is profitable. And growing rapidly.
$CHUC management knows a TON about FDA rules, owns tens of millions of shares, and has a compelling strategic plan.
With ZERO warrants, no short thesis whatsoever, and plans for a 2026 uplist,
$CHUC is poised to be one of the best microcap investments for 2026.
Do your own due diligence.
